As Alnylam Files to Begin Testing Cholesterol Drug in Humans, Questions Linger Over Delivery Tech
July 14, 2011
As Alnylam Files to Begin Testing Cholesterol Drug in Humans, Questions Linger Over Delivery Tech
Alnylam said that the drug candidate is the first to incorporate the company's second-generation lipid nanoparticle technology. However, Alnylam is currently embroiled in a lawsuit with partner Tekmira Pharmaceuticals over ownership of that very delivery technology.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Tekmira Stops Phase I Trial of Cholesterol Drug, Plans to Move New Agent into Clinical Trials Later This Year
January 14, 2010 / Gene Silencing News - Alnylam Finds Partner for Cholesterol Program in The Medicines Company
February 7, 2013 / Gene Silencing News - Oligo Drugs Advance in the Clinic in 2012 as Delivery Hurdles are Addressed
January 3, 2013 / Gene Silencing News - Alnylam ATTR Program on Track as Company Explores Subcutaneous Delivery for Cholesterol Drug
November 8, 2012 / Gene Silencing News - Alnylam Focuses on Two Lead Programs, Won't Advance Others without Partners
January 12, 2012 / Gene Silencing News